Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NICOX<br />
1681 route des Dolines<br />
Les Taissounières - HB4 - BP 313<br />
06906 SOPHIA ANTIPOLIS - FRANCE<br />
Phone: +33 4 97 24 53 00<br />
Fax: +33 4 97 24 53 99<br />
Email: nicox@nicox.com<br />
Web site: www.nicox.com<br />
Contact: Gavin SPENCER<br />
NicOx is a pharmaceutical company focused on the research, development and<br />
future commercializ<strong>at</strong>ion of drug candid<strong>at</strong>es. NicOx is applying its proprietary nitric<br />
oxide-don<strong>at</strong>ing R&D pl<strong>at</strong>form to develop an internal portfolio of New Molecular<br />
Entities (NMEs) for the potential tre<strong>at</strong>ment of inflamm<strong>at</strong>ory, cardio-metabolic and<br />
ophthalmological diseases.<br />
NicOx’s lead investig<strong>at</strong>ional compound is naproxcinod, an NME in development for the<br />
relief of the signs and symptoms of osteoarthritis. In addition to naproxcinod, NicOx’s<br />
pipeline includes several nitric oxide-don<strong>at</strong>ing NMEs, which are in development<br />
internally and with partners, including Merck (known as MSD outside the United<br />
St<strong>at</strong>es and Canada) and Bausch + Lomb, for the tre<strong>at</strong>ment of select cardiovascular<br />
indic<strong>at</strong>ions, eye diseases and derm<strong>at</strong>ological diseases.<br />
NOKAD<br />
4 rue Pierre Fontaine<br />
91000 EVRY - FRANCE<br />
Phone: +33 1 60 87 89 86<br />
Fax: +33 1 60 87 89 99<br />
Email: contact@nokad-pharma.com<br />
Web site: www.nokad.fr<br />
Contact: Amine M. ABINA<br />
NOKAD has developed a target valid<strong>at</strong>ion pl<strong>at</strong>form using both in vivo and ex vivo<br />
models allowing the discovery of new p<strong>at</strong>hways in hem<strong>at</strong>ology and cancer with the<br />
aim to develop new therapeutic str<strong>at</strong>egies and biomarkers. NOKAD is developing a<br />
biomarker blood test to str<strong>at</strong>ify an individual risk of developing thrombosis following<br />
Erythropoietin tre<strong>at</strong>ment and in hypoxia-stressed p<strong>at</strong>ients. Other projects under<br />
development include therapeutic vaccin<strong>at</strong>ion in cancer and development of new<br />
vaccine str<strong>at</strong>egies in infectious diseases.<br />
52
Change language